Trial Profile

A Phase 1/2 Multicenter, Open-Label, Dose-escalation and Expansion Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2025 According to a TransCode Therapeutics media release, preliminary data to be presented in a poster session at ESMO Congress October 17-21, 2025, taking place in Berlin, Germany. (FPN: 983P)
14 Nov 2025 According to a TransCode Therapeutics media release, data analysis and monitoring are ongoing. A final clinical study report, scientific presentations and publications are planned.
14 Nov 2025 According to a TransCode Therapeutics media release, the company announced the completion of Phase 1a clinical trial with TTX-MC138.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com